BioFire Filmarray – bioMerieux syndromic testing system, exclusively distributed by Mediclim, detects within hours pathogens responsible for respiratory infections, meningitis, sepsis, gastrointestinal infections

Bucharest, March26, 2024 – Mediclim Group, one of the main players in the IVD market, invests annually more than 1 million euros in bringing innovative technologies to the Romanian diagnostic market with the main objective of significantly improving both the quality of diagnosis and the public health. More than 300 clinical studies published in prestigious journals show the advantages of syndromic testing with the BioFire Filmarray – bioMerieux system: the patient is diagnosed quickly, the appropriate treatment initiated quickly, thus reducing hospital days and treatment costs per patient.

Mediclim has also started the investment process to bring on the Romanian market IT&Data solutions with applicability in the medical field, which offer real benefits to the medical system by statistically processing the existing data in each hospital and providing reports that allow informed decision making by management teams.

The BioFire Filmarray – bioMerieux system uses multiplex PCR technology for rapid simultaneous molecular testing for multiple microorganisms (bacterial, viral or fungal pathogens) and reduces the time for microbiological diagnosis of a bacterial infection to a few hours compared to several days for equipment not using this technology.

„Single syndromic diagnostic tests for pneumonia and sepsis may even save the lives of patients with these infectious diseases, when a rapid result is a critical factor for therapeutic success”, explained Mircea Ciupe, co-founder and shareholder of Mediclim. „Rapid diagnosis in these severe pathologies allows appropriate treatment to be instituted quickly and reduces the number of additional tests. Furthermore, the system also identifies antimicrobial resistance genes, thereby helping to identify and administer the most effective antibiotic treatment”, added Mircea Ciupe.

Mediclim Group operates in Romania, the Republic of Moldova and Bulgaria and recorded consolidated revenue of €26.7 million in 2023, up from €24.1 million in 2022.

„The results recorded in 2023 confirm Mediclim’s position as market leader in the IVD segment in Romania and give us a solid outlook for this year, when we celebrate three decades since our foundation and in which we aim for double-digit revenue growth at group level”, said Anda Ciupe, co-founder and majority shareholder of Mediclim. „ Equipment and reagents for Microbiology, Immunology, Immunohematology, Molecular Diagnostics and tests for microbiological control of food, water and veterinary diagnostics will remain the main growth drivers in 2024. In addition, we are pleased to have pioneered the syndromic testing segment last year with the BioFire-bioMerieux system using multiplex PCR technology. One of our main objectives this year is to strengthen our presence in this sector”, added Anda Ciupe.

Mediclim delivers IVD equipment and solutions to private medical networks including Regina Maria, Medlife, Bioclinica, Synevo, Gral Medical, Clinica Sante, Sanador; to private medical laboratories, including “Dr. Victor Babes” Foundation, Teo Health SA – Hospital Sf. Constantin Brasov, AAYLEX ONE SA, Fabrica de Lapte Brasov SA and to public health units, among the major projects are those carried out at the hospitals: the National Institute of Blood Transfusion “Prof.Dr. C. T. Nicolau” Bucharest, the National Institute of Infectious Diseases “Prof. Dr. Matei Balș”, the Central Military Emergency Hospital “Dr. Carol Davila”, the County Emergency Hospital Bihor, the Clinical Hospital of Infectious and Tropical Diseases “Dr. Victor Babeș” Bucharest, the Regional Institute of Gastroenterology and Hepatology “Prof. Dr. Octavian Fodor” Cluj, the County Emergency Hospital “Sf. Apostol Andrei” Galati. .

The company’s suppliers include bioMérieux SA France, Abbott Laboratories USA, SAS Diagast France, IDEXX Laboratories INC. USA, Microbiologics INC USA, Erba Mannheim UK.

Share

Share